Mid-sized Indian pharma firms revamp strategies amid US tariff concerns, focusing on NCDs, API manufacturing, emerging ...

Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Carbamazepine Tablets USP, ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...

Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate. ... Read More The post Health Check: Trump says a pharma tax is in the offing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Healthcare stocks ended a volatile Wall Street week on a positive note. Explore top movers, Novartis' $23B U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...